News and Announcements
Analytica Granted Patent Protection for PeriCoach® in Australia
- Published May 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Analytica (ASX: ALT) has been granted patent protection in Australia for the PeriCoach® System’s unique pelvic floor force sensing technology.
KEY TAKEAWAYS:
- Patents on the PeriCoach force sensors have now been issue in China, Japan and Australia.
- With patents pending in US, India, Brazil and Europe.
- The patent has a term of 20 years from 9 January 2012.
- It has remained a top priority to ensure that PeriCoach becomes a global product, therefor Analytica has maintained its investment in intellectual protection in major markets around the world.
- The intellectual property strategy remains to secure protection in key geographies that have ageing populations, with increased awareness of urinary incontinence, and growing treatment solutions.
Analytica CEO Geoff Daly said – “Continuing to develop and secure our intellectual property in key global markets is important to licencing partners, as it provides them the freedom to take our Australian inventions to the world. Australia is an attractive location to conduct R&D and most of Analytica’s research takes place here. The Federal Government’s decision to maintain the R&D tax incentive provides welcome assurance that it will remain that way.”
Analytica’s lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.
PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
